BioInvent's Tie-Up With Cancer Research Technology Brings Some Relief From Pipeline Setbacks

Sweden's BioInvent forges links with researchers at Queen Mary, University of London, and Cancer Research Technology, the commercial arm of charity Cancer Research UK, to identify new therapeutic antibodies for oncology.

A week after BioInvent International AB reported disappointing news on two of its early clinical programs, the Lund, Sweden-based biotech had better news to impart June 11 when it announced a collaborative agreement with Cancer Research Technology Ltd. and Queen Mary, University of London, on identifying new potential therapeutic antibodies for cancer indications.

Researchers at Queen Mary led by senior research fellow Thorsten Hagemann and funded by Cancer Research UK will use...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United Kingdom

More from Europe